Cargando…
The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma
CONTEXT: Growth hormone pituitary adenoma (GHPA), a major subtype of pituitary adenoma (PA), can lead to progressive somatic disfigurement, multiple complications, and even increased mortality. The efficacy of current treatments is limited; thus, a novel pharmacological treatment is urgently needed....
Autores principales: | Ji, Chenxing, Xu, Wen, Ding, Hong, Chen, Zhengyuan, Shi, Chengzhang, Han, Jie, Yu, Liang, Qiao, Nidan, Zhang, Yichao, Cao, Xiaoyun, Zhou, Xiang, Cheng, Haixia, Feng, Huijin, Luo, Cheng, Li, Zhiyu, Zhou, Bing, Ye, Zhao, Zhao, Yao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113810/ https://www.ncbi.nlm.nih.gov/pubmed/35247260 http://dx.doi.org/10.1210/clinem/dgac128 |
Ejemplares similares
-
Ectopic recurrence craniopharyngioma: series report and literature review
por: Ji, Chenxing, et al.
Publicado: (2023) -
BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma
por: Shi, Chengzhang, et al.
Publicado: (2020) -
Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma
por: Lin, Ben, et al.
Publicado: (2022) -
Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma
por: Wang, Meng, et al.
Publicado: (2022) -
Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver
por: Zhang, Yichao, et al.
Publicado: (2021)